Intercellular communication through extracellular vesicles in cancer and evolutionary biology.


Journal

Progress in biophysics and molecular biology
ISSN: 1873-1732
Titre abrégé: Prog Biophys Mol Biol
Pays: England
ID NLM: 0401233

Informations de publication

Date de publication:
10 2021
Historique:
received: 19 02 2021
revised: 04 08 2021
accepted: 10 08 2021
pubmed: 16 8 2021
medline: 26 11 2021
entrez: 15 8 2021
Statut: ppublish

Résumé

Extracellular vesicles (EVs) are nano-sized membrane enclosed vesicles that are released by cells. While initially thought to be cellular detritus or particles involved in eliminating waste from cells, EVs have been recognised as important mediators of intercellular communication by transferring their bioactive cargoes. Notably, over the last two decades, a substantial research effort has been undertaken to understand the role of EVs in cancer. It is now understood that tumour derived EVs can transfer their contents to influence metastatic behaviour, as well as establish favourable microenvironments and pre-metastatic niches that support cancer development and progression. EV-mediated intercellular communication in cancer will be of importance to understanding the emerging paradigm which views cancer as the establishment of a new species within the host organism. Here, we provide a concise overview of EVs and the current understanding of their role and application in cancer. In addition, we explore the potential wider role of EVs in the transfer of inherited characteristics and evolutionary biology.

Identifiants

pubmed: 34391800
pii: S0079-6107(21)00099-7
doi: 10.1016/j.pbiomolbio.2021.08.006
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

80-87

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M011224/1
Pays : United Kingdom

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S.E.B. has equity in Evox Therapeutics Ltd. and holds an ongoing contract with Evox Therapeutics Ltd. from 2017 to present. Evox Therapeutics Ltd. had no influence on the conception or realisation of this review.

Auteurs

Scott E Bonner (SE)

Department of Paediatrics, University of Oxford, Oxford, United Kingdom.

Eduard Willms (E)

Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, Melbourne, Australia. Electronic address: e.willms@latrobe.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH